News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN)'s Future Shaky as Alzheimer's Program Crashes


8/8/2012 7:36:43 AM

Elan Corp. fell to the lowest price since December in Dublin trading after the company's partners ended most plans to develop an Alzheimer's drug following a second failure in a clinical trial. Elan will take a charge of $117.3 million this quarter, writing down to zero the value of its venture with Johnson & Johnson to develop the drug, bapineuzumab, the Irish company said Monday. Now that J&J and Pfizer Inc. are ending most work on the treatment, Elan will have "a significant reduction in spending" through the end of 2013, the company said.

Read at SF Gate
Read at BusinessWeek
Read at Market Watch
Read at TheDeal.com
Read at Minyanville
Read at Independent


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES